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Background: Homeobox genes encode transcription factors that control patterning of virtually all organ systems
including the vasculature. Tumor angiogenesis is stimulated by several homeobox genes that are overexpressed
in tumor cells, but the mechanisms of these genes are poorly understood. In this study, we investigated the
mechanisms by which DLX4, a homeobox gene that is associated with increased tumor microvessel density,
stimulates ovarian tumor angiogenesis.
Methods: Expression of DLX4 and nitric oxide synthases was analyzed in publicly available transcriptional profiles
of ovarian cancer clinical specimens. Levels of inducible nitric oxide synthase (iNOS) were evaluated by quantitative
RT-PCR, flow cytometry and nitric oxide assays using ovarian cancer cell lines in which DLX4 was overexpressed or
knocked down. Signal Transducer and Activator of Transcription 1 (STAT1) expression and activity were evaluated
by luciferase reporter assays, immunofluorescence staining, Western blot and immunoprecipitation. Endothelial cell
growth and tumor angiogenesis were evaluated in in vitro assays and xenograft models.
Results: We identified that DLX4 induces expression of iNOS, an enzyme that stimulates angiogenesis by
generating nitric oxide. Analysis of datasets of two independent patient cohorts revealed that high DLX4 expression
in ovarian cancer is strongly associated with elevated expression of iNOS but not of other nitric oxide synthases.
Studies using STAT1-expressing and STAT1-deficient cells revealed that DLX4 interacts with STAT1 and induces iNOS
expression in part by stimulating STAT1 activity. Expression of DLX4 in ovarian cancer cells stimulated endothelial
cell growth in vitro and increased microvessel density in xenograft models, and these stimulatory effects of DLX4
were abrogated when its induction of iNOS was inhibited.
Conclusion: These findings indicate that DLX4 promotes ovarian tumor angiogenesis in part by stimulating iNOS
expression.
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Angiogenesis is a tightly regulated process that is essential
for normal organ development, tissue repair and regener-
ation, and tumor growth. Growth, maturation and migra-
tion of endothelial cells and vessel formation are controlled
by environmental cues such as nitric oxide (NO) and hyp-
oxia, and a network of growth factors, receptors and tran-
scription factors [1-3]. Among the transcription factors that
control angiogenesis, the most extensively studied include* Correspondence: hnaora@mdanderson.org
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unless otherwise stated.hypoxia-inducible factors (HIF), nuclear factor κB (NF-κB)
and members of the Signal Transducer and Activator of
Transcription (STAT) and E-twenty-six (ETS) families of
transcription factors [3-6].
The homeobox gene super-family comprises more than
200 vertebrate genes and encodes transcription factors,
termed homeoproteins, that are characterized by their con-
served helix-turn-helix DNA-binding domain [7]. Homeo-
proteins are expressed in a temporal- and tissue- specific
manner and play essential roles in controlling cell lineage-
specification and tissue morphogenesis [7-9]. Increasing
evidence indicates that angiogenesis is tightly regulated byhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lial cell migration and tube formation by activating tran-
scription of the gene encoding ephrin B4 [10]. HOXB5
promotes endothelial sprouting by inducing angiopoietin-2
expression [11]. In contrast, HOXA5, HOXD10 and GAX
exert inhibitory effects on angiogenesis by various mecha-
nisms such as inducing expression of thrombospondin-2
and p21WAF1/CIP1 [12-14].
Many homeobox genes have been found to be up- or
down- regulated in a variety of tumors [8,9]. The mecha-
nisms of most of these genes in tumor growth and progres-
sion are poorly understood as only few transcriptional
targets have been identified. Notably, several homeopro-
teins that are aberrantly expressed in tumor cells have been
found to control expression of pro-angiogenic growth fac-
tors. HOXB7 is overexpressed in more than 50% of breast
cancers and activates the gene that encodes fibroblast
growth factor-2 [15]. Conversely, loss of NKX3.1, which oc-
curs in 80% of prostate cancers, increases expression of vas-
cular endothelial growth factor (VEGF)-C [16]. High tumor
microvessel density is strongly predictive of poor outcomes
in patients with ovarian cancer [17,18]. We previously iden-
tified that DLX4, a homeoprotein that is absent from most
normal adult tissues, is expressed in approximately 50% of
ovarian cancers and is strongly associated with reduced sur-
vival [19]. Studies using xenograft models revealed that
DLX4 expression in ovarian cancer cells increases tumor
microvessel density, implicating a pro-angiogenic function
for DLX4 [19]. Inducible nitric oxide synthase (iNOS) is an
enzyme that promotes angiogenesis by generating NO
[2,20] and its expression in ovarian cancers is strongly asso-
ciated with poor outcomes [21,22]. In this study, we identi-
fied that DLX4 induces iNOS expression in part by
stimulating STAT1 activity and promotes ovarian tumor
angiogenesis by inducing iNOS expression. These findings
raise the possibility that specific sets of homeoproteins pro-
mote tumor angiogenesis not only by directly regulating
transcription of angiogenic growth factors, but also by
modulating intracellular signaling and environmental cues.
Results
DLX4 induces iNOS expression
In previous studies, we identified that DLX4 increases
tumor microvessel density in xenograft models of ovar-
ian cancer, but the underlying mechanism of DLX4 was
not clear [19]. Because iNOS is frequently expressed in
ovarian cancers and stimulates tumor angiogenesis
[2,20-22], we investigated the possibility that DLX4 stim-
ulates iNOS expression. Stronger staining of iNOS was
detected in xenografts derived from ES2 ovarian cancer
cells that stably expressed DLX4 (+DLX4) than in xeno-
grafts derived from vector-control ES2 cells [Figure 1A].
Flow cytometric analysis of intracellular iNOS staining
in cultured ES2 cells revealed that enforced expressionof DLX4 induced a 4-fold increase in iNOS levels
[Figure 1B]. Similarly, enforced expression of DLX4 in
A2780 ovarian cancer cells induced iNOS levels [Figure 1C].
To confirm our findings, we evaluated iNOS levels when en-
dogenous DLX4 was knocked down by two different DLX4
shRNAs (shDLX4-A, shDLX4-B). Levels of iNOS were de-
creased when endogenous DLX4 was knocked down in
2008 cells [Figure 1D]. Furthermore, iNOS levels were de-
creased when DLX4 was knocked down in three additional
ovarian cancer cell lines (OVCAR8, OVCA429 and
TOV112D) [Additional file 1: Figures S1 A,B and C].
Changes in iNOS expression were confirmed by quanti-
tative reverse transcription PCR (qRT-PCR) analysis of
NOS2 mRNA levels. NOS2 mRNA levels significantly
increased when DLX4 was overexpressed (P < 0.001)
[Figure 1E], and decreased when DLX4 was knocked
down (P < 0.001) [Figure 1F]. We also assayed mRNA
levels of NOS1 (encoding neuronal nitric oxide synthase
nNOS) and NOS3 (encoding endothelial nitric oxide
synthase eNOS). NOS1 and NOS3 mRNA levels were
detected in A2780 and 2008 cells, but were almost un-
detectable in ES2 cells and other ovarian cancer cell
lines that we tested. In contrast to NOS2, mRNA levels
of NOS1 and NOS3 did not significantly change when
DLX4 was overexpressed in A2780 cells or when DLX4
was knocked down in 2008 cells [Figure 1E and F].
Elevated expression of DLX4 is associated with increased
iNOS expression in ovarian cancer clinical specimens
To evaluate whether iNOS expression is elevated in ovar-
ian cancers that highly express DLX4, we analyzed pub-
lished, publicly available transcriptional profiles of clinical
specimens from the Australian Ovarian Cancer Group
Study [23]. Cases from this dataset (n =285) were stratified
into quartile sub-groups according to the levels of DLX4
transcripts in tumors. Levels of NOS2 transcripts were sig-
nificantly higher in DLX4-High tumors (upper quartile
sub-group) than in DLX4-Low tumors (lower quartile
sub-group) (P = 0.016) [Figure 2]. Levels of NOS2 tran-
scripts were also significantly higher in DLX4-High
tumors than in DLX4-Low tumors (P = 0.021) in an inde-
pendent patient cohort (n = 260 cases) from the Japanese
Serous Ovarian Cancer Group Study [24]. In contrast to
NOS2, no significant differences were found in expression
levels of NOS1 and NOS3 between DLX4-High and
DLX4-Low cases in the two cohorts [Figure 2]. These ob-
servations are consistent with our findings that DLX4 in-
duces expression of NOS2 but does not alter expression of
NOS1 or NOS3 in ovarian cancer cells [Figure 1E and F].
DLX4 induces iNOS expression in a STAT1-dependent
manner
DLX4 has been reported to regulate expression of several
genes by modulating activity of other transcription factors
Figure 1 DLX4 induces iNOS expression. (A) Staining of iNOS in sections of peritoneal tumors of mice that were inoculated with vector-control
and +DLX4 ES2 lines. Bar, 20 μm. (B, C and D) Flow cytometric analysis of intracellular staining of DLX4 and iNOS in transfected ovarian cancer
cell lines. Mean fluorescence intensities (MFI) of staining are indicated. Shown are representative examples of DLX4 and iNOS staining in (B)
vector-control and +DLX4 ES2 cells, (C) vector-control and +DLX4 A2780 cells and (D) 2008 cells transfected with non-targeting shRNA and
shRNAs that targeted two different regions of DLX4 (shDLX4-A, shDLX4-B). (E) qRT-PCR analysis of relative NOS2 mRNA levels in ES2 cells and
NOS1, NOS2 and NOS3 mRNA levels in A2780 cells. Levels of each mRNA in +DLX4 cells are expressed relative to the level in vector-control cells.
(F) qRT-PCR analysis of relative NOS1, NOS2 and NOS3 mRNA levels in 2008 cells. Levels of each mRNA in DLX4 shRNA-transfected cells are
expressed relative to the level in non-targeting shRNA-transfected cells.
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tional activator of NOS2 [26,27]. Induction of NOS2
mRNA levels by DLX4 in ES2 cells was abrogated by adominant-negative STAT1 Y701F mutant [28] (STAT1-
dn) (P < 0.001) [Figure 3A]. We also evaluated the effect
of a mutant form of DLX4 (DLX4-TA) that lacks the
Figure 2 High expression of DLX4 is associated with increased iNOS expression in clinical specimens of ovarian cancer. Cases from the Australian Ovarian
Cancer Group Study [23] (GSE9891, n = 285) were stratified according to DLX4 expression in tumors, where DLX4 mRNA levels were defined as High
(≥ upper quartile) and Low (≤ lower quartile). Significance of differences in NOS1, NOS2 and NOS3 mRNA levels (log2 scale) between upper and lower
quartile sub-groups was evaluated by Mann–Whitney U-test. The same analysis was performed for cases from the Japanese Serous Ovarian Cancer Group
Study [24] (GSE32062, n = 260).
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cleus [25,29]. This DLX4 mutant did not induce NOS2
mRNA levels [Figure 3A]. Together, these findings indi-
cated that DLX4 induces iNOS expression in a STAT1-
dependent manner and raised the possibility that DLX4
might stimulate STAT1 activity. To evaluate the effect of
DLX4 on STAT1 activity, we assayed activity of a luciferaseFigure 3 DLX4 stimulates STAT1 activity and induces iNOS expression in a
levels in vector-control ES2 cells and in ES2 cells that expressed wild-type D
STAT1 (STAT1-dn). (B) Vector-control ES2 cells and ES2 cells that expressed
reporter construct driven by GAS elements (GAS-LUC), stimulated without o
activity. (C) Activity of the GAS-LUC reporter construct was assayed in 2008
(B). (D) Western blot analysis of levels of total STAT1 and phosphorylated S
IFN-γ (10 ng/mL) for 0, 1, 6 and 18 h. (E) Lysates of U3A cell lines that lacke
DLX4 fused to GFP were assayed by Western blot using Abs to STAT1 and
U3A cells and in U3A cells reconstituted with STAT1 that lacked or express
(10 ng/mL) for 16 h and then assayed for luciferase activity. (G) FLAG Ab w
stimulated with IFN-γ (10 ng/mL) for 1 h. Immunoprecipitates were analyze
included as a negative control. Shown in B, C and F are relative firefly lucifreporter construct driven by STAT1-binding, interferon
(IFN) Gamma-Activated Sites (GAS) elements (GAS-LUC).
Enforced expression of wild-type DLX4 in ES2 cells signifi-
cantly induced GAS-LUC reporter activity (P < 0.0001)
[Figure 3B]. In contrast, GAS-LUC reporter activity was not
induced by the DLX4-TA mutant [Figure 3B]. To confirm
our findings, we evaluated GAS-LUC reporter activity whenSTAT1-dependent manner. (A) qRT-PCR analysis of relative NOS2 mRNA
LX4 or mutant DLX4 (DLX4-TA) with or without dominant-negative
wild-type or mutant DLX4 were transfected with a firefly luciferase
r with IFN-γ (10 ng/mL) for 16 h and then assayed for luciferase
cells that expressed non-targeting and DLX4 shRNAs as described in
TAT1 in vector-control and +DLX4 ES2 cells that were stimulated with
d or stably expressed GFP-STAT1 fusion protein and/or FLAG-tagged
DLX4. (F) Activity of the GAS-LUC reporter construct in STAT1-deficient
ed DLX4. Transfected cells were stimulated with or without IFN-γ
as used to pull down FLAG-tagged DLX4 in U3A cells that were
d by Western blot using Ab to STAT1. Pulldown using control Ig was
erase activities in three independent experiments.
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activity was inhibited when DLX4 was knocked down in
2008 cells (P < 0.01) [Figure 3C] and also in OVCAR8 and
TOV112D cells (P < 0.01) [Additional file 1: Figure S2].
DLX4 interacts with STAT1 and stimulates STAT1
expression and activity
To further investigate the stimulatory effect of DLX4 on
STAT1, we evaluated its effects on STAT1 phosphorylation
and expression. Following IFN-γ stimulation, higher levels
of phosphorylated STAT1 were detected in +DLX4 ES2
cells than in vector-control ES2 cells [Figure 3D]. Consist-
ent with this observation, higher levels of STAT1 were de-
tected in the nucleus of +DLX4 ES2 cells [Additional file 1:
Figure S3]. The increases in STAT1 phosphorylation and
nuclear localization in +DLX4 cells corresponded to an in-
crease in the expression level of STAT1 [Figure 3D]. Be-
cause transcription of the STAT1 gene is controlled in part
by a GAS element [30], we evaluated the effect of DLX4 on
STAT1 activity independently of its induction of STAT1 ex-
pression. To accomplish this, we used the STAT1-deficient
fibrosarcoma cell line U3A [31] as a model and reconsti-
tuted STAT1 expression in this cell line under the control
of the constitutive CMV promoter [Figure 3E]. DLX4 was
stably expressed in both STAT1-deficient and STAT1-
reconstituted U3A cells [Figure 3E]. DLX4 significantly in-
duced GAS-LUC reporter activity in U3A cells that stably
expressed STAT1 (P < 0.001) [Figure 3F]. This finding indi-
cated that DLX4 stimulates STAT1 activity per se. Immu-
noprecipitation (IP) assays revealed that DLX4 interacts
with STAT1 [Figure 3G]. DLX4 might therefore induce
iNOS expression by interacting with and stimulating
STAT1 activity.
DLX4 stimulates VEGF-A production and endothelial cell
growth in vitro by inducing iNOS
A major mechanism by which iNOS promotes angiogenesis
is by generating NO that stimulates VEGF-A expression
[32,33]. In subsequent experiments, we sought to determine
whether DLX4 stimulates NO and VEGF-A production in
tumor cells by inducing iNOS. We evaluated whether the
stimulatory effects of DLX4 are abrogated when its induc-
tion of iNOS is inhibited. To accomplish this, we stably
knocked down the level of iNOS in +DLX4 ES2 cells almost
to the level seen in vector-control ES2 cells [Figure 4A].
Levels of NO and VEGF-A were assayed in cell culture
medium that was conditioned by equivalent numbers of
cells of each ES2 line. DLX4 induced levels of NO and
VEGF-A (P < 0.01), and this induction was abrogated
when iNOS was knocked down (i.e. +DLX4 + shNOS2)
[Figure 4B and C]. Endothelial cell growth was more
highly stimulated by medium that was conditioned by
+DLX4 cells than by medium conditioned by vector-
control cells (P < 0.01) [Figure 4D]. In contrast, mediumconditioned by +DLX4 + shNOS2 cells was only as ef-
fective as medium conditioned by vector-control cells in
stimulating endothelial cell growth [Figure 4D]. These
findings indicate that the stimulatory effects of DLX4
on VEGF-A production and endothelial cell growth are
substantially mediated through its induction of iNOS.
Stimulatory effects of DLX4 on ovarian tumor
angiogenesis and ascites formation are mediated through
its induction of iNOS in vivo
To confirm our in vitro findings, we evaluated whether
DLX4 stimulates ovarian tumor angiogenesis via its induc-
tion of iNOS by generating mouse i.p. xenograft models
from vector-control and +DLX4 ES2 cells and from+DLX4
ES2 cells in which iNOS was knocked down. Enforced ex-
pression of DLX4 induced ascites formation, and knock-
down of iNOS in +DLX4 models reduced ascites almost to
the level seen in vector-control models [Figure 5A]. Con-
sistent with our previous studies [19], DLX4 increased
tumor microvessel density [Figure 5B and C]. Knockdown
of iNOS in +DLX4 xenograft models reduced microvessel
density to a level comparable to that seen in vector-control
models [Figure 5B and C]. Together, our findings indicate
that the stimulatory effect of DLX4 on ovarian tumor
angiogenesis is substantially mediated through its induction
of iNOS.
Discussion
Several homeoproteins that are expressed in endothelial
cells play important roles in transcriptional programs that
control normal endothelial cell growth, migration and tube
formation [10-14]. Increasing evidence indicates that aber-
rant expression of other sets of homeoproteins in tumor
cells increases tumor angiogenesis (reviewed in Ref. [9]),
but their mechanisms are poorly understood. In this study,
we identified that DLX4, a homeoprotein that is overex-
pressed in ovarian cancer, stimulates ovarian tumor angio-
genesis by inducing iNOS expression. To our knowledge,
our study is the first to identify a role for a homeoprotein
in controlling NO generation. NO is generated from L-
arginine, NADPH and oxygen by NO synthases of which
there are three isoforms [2,20]. nNOS and eNOS are con-
stitutively expressed, predominantly in neuronal cells and
endothelial cells, respectively, and are also expressed in
several types of tumors including a subset of ovarian can-
cers [2,20,34]. iNOS produces substantially more NO than
the other NO synthase isoforms [2]. We found that high
DLX4 expression is associated with increased expression
of iNOS but not of nNOS or eNOS in clinical specimens
of ovarian cancer, and that DLX4 induces expression of
iNOS but not of nNOS or eNOS in ovarian tumor cells. A
principal mechanism by which NO promotes angiogenesis
is by increasing VEGF-A production [32,33]. Our findings
that the stimulatory effects of DLX4 on VEGF-A
Figure 4 DLX4 stimulates NO levels, VEGF-A production and endothelial cell growth in vitro by inducing iNOS. (A) Flow cytometric analysis of iNOS levels
in vector-control and +DLX4 ES2 cells, and in +DLX4 ES2 cells that stably expressed NOS2 shRNA (+DLX4 + shNOS2). (B) NO levels were assayed by using
Griess reagent in culture medium that was conditioned by equivalent numbers of cells of each ES2 line. (C) Levels of VEGF-A were assayed by ELISA in
tumor-conditioned medium. (D) Growth of endothelial cells cultured in tumor-conditioned medium was evaluated by MTT assay. Shown in B, C and D are
average results of three independent experiments.
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iNOS is inhibited support the conclusion that these stimu-
latory effects of DLX4 are primarily mediated via its in-
duction of iNOS. In addition to its potent angiogenic
property, VEGF-A causes ascites formation in ovarian
cancer [35]. DLX4 expression in ovarian tumor cells in-
duced ascites formation in mice and this induction was
abrogated when iNOS was inhibited. Agents that
neutralize VEGF-A or inhibit VEGF receptor tyrosine kin-
ase activity have been extensively evaluated in clinical tri-
als of ovarian cancer patients and a limitation of these
agents is acquired resistance [36]. Inhibition of iNOS
might be an effective approach to inhibit tumor angiogen-
esis and also ascites formation in ovarian cancer.
The findings of the present study indicate that DLX4
interacts with STAT1 and induces iNOS expression at
least in part by stimulating STAT1 activity. Although
dominant-negative STAT1 abrogated the ability of
DLX4 to induce iNOS expression, we cannot eliminate
the possibility that DLX4 might also stimulate activity
of other transcription factors that activate NOS2 tran-
scription such as NF-κB and HIF-1α [27,37]. To our
knowledge, our study is the first to identify aninteraction between a homeoprotein and a member of
the STAT family. Although the precise mechanism by
which DLX4 stimulates STAT1 activity remains to be de-
termined, it is possible that DLX4 stabilizes STAT1-
containing transcriptional complexes. Whereas inflamma-
tory cytokines induce NOS2 transcription, transforming
growth factor-β (TGF-β) decreases NOS2 mRNA stability
and translation and increases degradation of iNOS pro-
tein [38]. We previously identified that DLX4 blocks
TGF-β/Smad signaling [25]. It is therefore possible that
DLX4 might also increase levels of iNOS by blocking
TGF-β-mediated NOS2 mRNA destabilization and
iNOS protein degradation. Whereas iNOS induces
VEGF-A production, VEGF-A stimulation reciprocally
increases expression of iNOS [39]. DLX4 might add-
itionally, through its induction of iNOS, enhance the
iNOS-VEGF-A regulatory loop in tumors.
Whereas NO has a pro-tumorigenic effect by stimulating
angiogenesis, continuous exposure to NO at high concen-
trations exerts genotoxic effects [20]. Metabolites of NO
can cause DNA damage and lead to cell death [20]. NO has
been reported to induce expression of the catalytic subunit
of DNA-dependent protein kinase (DNA-PK), an essential
Figure 5 DLX4 stimulates tumor angiogenesis and ascites formation in i.p. xenograft models of ovarian cancer by inducing iNOS. Female nude mice
(n = 5 per group) were inoculated i.p. with equivalent numbers of cells (1 x 106) of vector-control, +DLX4 and +DLX4 + shNOS2 ES2 lines and sacrificed
at 20 days thereafter. (A) Volume of ascites. (B) Average numbers of microvessels were calculated in omental tumors by scoring five random 100x
microscopic fields of CD34-stained tissue sections of each mouse. (C) Representative examples of CD34 staining in omental tumors. Bar, 100 μm.
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DNA repair machinery [40]. This NO-mediated induction
of DNA-PK has been found to protect cells from the dele-
terious effects of NO and other DNA damaging agents
[40]. We recently identified that DLX4 stimulates DNA-PK
activity and NHEJ-mediated DNA repair by interacting
with Ku70 and Ku80 that bind to DNA double-strand
break ends [29]. This activity of DLX4 protected tumor
cells against DNA damaging chemotherapeutic agents such
as doxorubicin and etoposide [29]. It is possible that DLX4
might similarly protect tumor cells against the genotoxic ef-
fects of high NO levels by stimulating repair of DNA dam-
age caused by NO metabolites. In addition, several studies
have identified that STAT1 confers resistance to DNA dam-
age (reviewed in Ref. [41]). DLX4 might also confer resist-
ance to NO-induced DNA damage by stimulating STAT1
activity.
Because relatively few transcriptional targets of homeo-
proteins have been identified, it is unclear how the tumor-
promoting properties of these factors are related to their
normal developmental functions. The DLX4 gene was ori-
ginally identified in a screen of a placental cDNA library
[42] but its normal function is poorly understood. Pre-
eclampsia is characterized by reduced placental blood flow
and elevated maternal blood pressure, and is a major
cause of fetal and maternal morbidity and mortality [43].
Substantial evidence indicates that disruption of NObioavailability contributes to the pathophysiology of pre-
eclampsia and that expression of iNOS is reduced in pre-
eclamptic placentas [43-45]. Interestingly, it has also been
reported that DLX4 expression is down-regulated in pre-
eclamptic placentas [46]. Our findings that DLX4 induces
iNOS expression raise the intriguing possibility that
down-regulation of DLX4 in the placenta might promote
endothelial dysfunction in preeclampsia by causing a re-
duction in iNOS levels.
Conclusion
In summary, the present study supports increasing evi-
dence of the significance of homeoproteins in the regula-
tion of angiogenesis. Whereas prior studies have shown
that homeoproteins control expression of angiogenic
growth factors or receptors [10,11,13,15,16], our findings
indicate that homeoproteins can also promote angiogen-
esis by modulating intracellular signaling and environ-
mental cues. Because homeoproteins are transcription
factors that share a conserved DNA-binding domain, it
could be difficult to therapeutically target these proteins
with high specificity. A peptide that disrupts interactions
of specific HOX proteins with PBX co-factors has been re-
ported to inhibit tumor cell growth [47]. It might there-
fore be possible to inhibit the tumor-promoting functions
of homeoproteins such as DLX4 by disrupting their inter-
actions with binding partners.
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Plasmids
The pIRES-EGFP2 plasmid encoding FLAG-tagged DLX4
has been previously described [25]. The DLX4 cDNA was
subcloned into the pRetroQ-AcGFP retroviral vector
(Clontech). Other plasmids were as follows: pGFP-V-RS
plasmids containing non-targeting and DLX4 shRNAs
(OriGene Technologies), pGIPZ plasmids containing NOS2
shRNAs (GE Healthcare), eGFP-STAT1 (provided by Alan
Perantoni, National Cancer Institute, Frederick, MD;
Addgene plasmid 12301) [48], pRc/CMV-Flag STAT1α
Y701F [28] (provided by James Darnell, Rockefeller Univer-
sity, New York, NY; Addgene plasmid 8702). A firefly lucif-
erase reporter construct driven by tandem GAS elements
was purchased from SABiosciences.
Antibodies (Abs) and other reagents
Sources of Abs were as follows: DLX4, iNOS, CD34
(Abcam), STAT1, phosphorylated STAT1 (Y701) (Cell
Signaling Technology), FLAG, actin (Sigma-Aldrich), sec-
ondary Abs (BD Biosciences, Invitrogen). Recombinant
IFN-γ was purchased from R&D Systems.
Cell culture and transfection
Culture media were purchased from Invitrogen and were
supplemented with penicillin-streptomycin and 10% fetal
bovine serum. Vector-control and DLX4-overexpressing
ES2 cell lines have been previously described [19] and
were cultured in McCoys’ 5A medium. The parental
2008 cell line was provided by Zahid Siddik (MD Ander-
son Cancer Center, Houston, TX) and cultured in RPMI
1640 medium. Parental A2780, OVCAR8 and OVCA429
cell lines were provided by Gordon Mills (MD Anderson
Cancer Center) and cultured in RPMI 1640 medium
(A2780, OVCAR8) and Dulbecco’s Modified Eagle’s
Medium (DMEM) (OVCA429). The parental TOV112D
cell line was provided by Ju-Seog Lee (MD Anderson
Cancer Center) and cultured in a 1:1 mixture of MCDB
105 medium and Medium 199. The U3A cell line [31]
was provided by George Stark (Cleveland Clinic Lerner
Research Institute, Cleveland, OH) and cultured in
DMEM. Immortalized mouse ovarian endothelial cells
[49] were provided by Isaiah Fidler (MD Anderson Can-
cer Center) and cultured in DMEM medium. Ampho-
293 cells were provided by Douglas Boyd (MD Anderson
Cancer Center) and cultured in DMEM. Ampho-293
cells were transfected with pRetroQ-AcGFP retroviral
constructs by using Lipofectamine®2000 reagent (Invitro-
gen). At 48 h thereafter, viral supernatants were harvested
and used to infect U3A and A2780 cells. In other experi-
ments, cultured cells were directly transfected with plas-
mids by using Lipofectamine®2000 reagent or FuGENE®6
reagent (Promega). Cells were selected by addition of
G418 (400 μg/mL) or puromycin (0.5 μg/mL).NO assay
Cells were cultured overnight in medium that contained
no FBS or Phenol Red. Culture supernatants were there-
after depleted of proteins that were >10 kD in size by cen-
trifugation at 14,000 × g for 10 mins through Amicon
Ultra 0.5 mL centrifugal filters (Millipore). NO levels in
supernatants were assayed by using Griess reagent (Total
NO and Nitrate/Nitrite Parameter Assay Kit, R&D Sys-
tems) following manufacturer’s instructions. Three inde-
pendent experiments were performed for each assay.
Conditioned medium and cell proliferation assays
Equivalent numbers of tumor cells (1.5×106) were seeded in
10 cm dishes and cultured in medium containing 2% FBS
for 2 d. Tumor-conditioned medium was assayed for VEGF-
A levels by ELISA (R&D Systems) and added to endothelial
cells. Endothelial cell growth was measured by using the
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
(MTT) assay (Roche). Three independent experiments were
performed for each assay.
qRT-PCR
NOS1, NOS2 and NOS3 mRNA levels were analyzed by
using primers and SYBR®Green qPCR Master Mix that were
purchased from SABiosciences. RPL32 transcript levels were
used as controls for normalization and were detected by
using the following primers: forward: 5′-ACAAAGCACAT
GCTGCCCAGTG-3′, reverse: 5′- TTCCACGATGGCTTT
GCGGTTC-3′.
Immunofluorescence staining of cultured cells
For analysis of staining by flow cytometry, cells were fixed in
1% paraformaldehyde (20 min at 4°C) and permeabilized in
0.1% saponin (15 min at room temperature). Thereafter,
cells were incubated with Abs to DLX4 (1:20) or to iNOS
(1:100) for 30 min at 4°C, washed and incubated with
peridinin-chlorophyll-protein complex-conjugated second-
ary Ab. Staining was detected by flow cytometry (FACS
Calibur, BD Biosciences). For analysis of staining by fluores-
cence microscopy, cells were plated in chamber slides, fixed
in 4% paraformaldehyde (20 min at 4°C) and permeabilized
in 0.1% Triton-X100 (15 min at room temperature). There-
after, cells were incubated with STAT1 Ab (1:100) for
30 min at 4°C, washed and incubated with Alexa Fluor
594-conjugated secondary Ab. Cells were stained with
diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) and
then viewed using an Eclipse 80i fluorescence micro-
scope (Nikon).
IP and immunoblotting
Cell extracts were prepared by lysing cells in M-PER buf-
fer (Pierce Biotechnology). For IP, 2 mg of cell extract was
pre-cleared with protein G agarose and incubated with
FLAG Ab or with control Ig using lysis buffer (20 mM
Trinh et al. Molecular Cancer  (2015) 14:97 Page 10 of 11Tris–HCl pH 8.0, 100 mM NaCl, 1% Nonidet P-40, 10%
glycerol, 2 mM EDTA). Cell extracts and immunoprecipi-
tates were subjected to SDS-PAGE and immunoblotting
using polyvinylidene fluoride membrane (GE Healthcare).Reporter assays
Cells were co-transfected with plasmids containing DLX4
cDNA or shRNAs, firefly luciferase reporter plasmid and
Renilla luciferase reporter plasmid to normalize transfec-
tion efficiency as previously described [25]. Where indi-
cated, recombinant IFN-γ (10 ng/mL) was added to cells at
24 h after transfection. At 16 h thereafter, luciferase activ-
ities were assayed by using the Dual-luciferase reporter
assay kit (Promega). Three independent experiments were
performed for each assay.Mouse i.p. xenografts
All animal studies were approved by the University of
Texas MD Anderson Cancer Center Institutional Animal
Care and Use Committee. Four-week-old female nude
mice were purchased from Charles River and inoculated
i.p. with 1 × 106 cells of ES2 lines (n = 5 mice per group).
At 3 weeks thereafter, mice were euthanized by CO2 as-
phyxiation. Volume of ascites was measured. Sections of
formalin-fixed, paraffin-embedded tissues were stained
with Abs to iNOS and CD34 and staining detected by
streptavidin-biotin-peroxidase and 3,3′-diaminobenzidine
(Dako). Microvessels were counted in 5 independent and
random 100x microscopic fields in stained tumor tissue
sections of each mouse.Bioinformatic analysis
Published gene expression data from Australian Ovarian
Cancer Group Study [23] (GSE9891, n = 285) and from
the Japanese Serous Ovarian Cancer Group Study [24]
(GSE32062, n = 260) were downloaded from the National
Center for Biotechnology Information Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/
geo). Patients were stratified according to expression of
DLX4 in tumors, where DLX4 transcript levels were de-
fined as High (≥ upper quartile) and Low (≤ lower
quartile).Statistical analysis
STATISTICA6 software (StatSoft Inc.) was used for stat-
istical analysis. Statistical significance of data of in vitro
and in vivo assays was assessed by unpaired two-tailed
Student’s t-test. Significance of differences in gene ex-
pression between groups of patients was assessed by
Mann–Whitney U-test. P values of < 0.05 were consid-
ered significant.Additional file
Additional file 1: Figure S1. Related to Figure 1. Knockdown of DLX4
decreases iNOS levels in ovarian tumor cells. Flow cytometric analysis of
intracellular staining of DLX4 and iNOS in (A) OVCAR8, (B) OVCA429
and (C) TOV112D cells, where cells of these lines were transfected with
non-targeting shRNA and shRNAs that targeted two different regions of
DLX4 (shDLX4-A, shDLX4-B). Shown are representative examples of
staining and mean fluorescence intensities (MFI). Solid grey histograms
represent staining with Abs to DLX4 and to iNOS. Dotted histograms
represent staining with isotype control. Figure S2. Related to Figure 3.
DLX4 stimulates STAT1-driven promoter activity. OVCAR8 and TOV112D
cells that expressed non-targeting and DLX4 shRNAs were transfected
with the GAS-LUC reporter construct, stimulated without or with IFN-γ
(10 ng/mL) for 16 h and then assayed for luciferase activity. Shown are
relative firefly luciferase activities in three independent experiments.
Figure S3. Related to Figure 3. Effect of DLX4 on STAT1 localization in
ovarian tumor cells. Immunofluorescence staining of STAT1 (shown in
red) in vector-control and +DLX4 ES2 cells that were stimulated with
IFN-γ (10 ng/mL) for 1 h or left unstimulated. Cells were also stained with
DAP1 (shown in blue) to visualize nuclei. Bar, 20 μm.
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